Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Provided By PR Newswire

Last update: Aug 15, 2024

Announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03 evaluating low dose LTI-03 (2.5 mg BID) in idiopathic pulmonary fibrosis ("IPF") patients, with positive trends observed in seven of the eight biomarkers evaluated